Document is current
Any future updates will be listed below
-
Authors
Priel, Eldar
Adatia, Adil
Kjarsgaard, Melanie
Nair, Parameswaran https://orcid.org/0000-0002-1041-9492
- License Information
-
More Information
Article History
Received: 2 February 2022
Accepted: 3 May 2022
First Online: 6 June 2022
Declarations
:
: Ethics approval was obtained from the Hamilton Integrated Research Ethics Board #10600.
: Not applicable.
: EP has no competing interests to report. MK has no competing interests to report. AA is supported by the Canadian Institute for Health Research/Canadian Allergy, Asthma, and Immunology Foundation/AstraZeneca/AllerGen Emerging Researcher Award in Allergic Asthma; PN reports grants and personal fees from AZ, grants from Novartis, grants and personal fees from Teva, grants from Sanofi, grants and personal fees from Roche, personal fees from Novartis, personal fees from Merck, personal fees from Equillium, and grants from Foresee, outside the submitted work. He is supported by the Frederick E. Hargreave Teva Innovation Chair in Airway Diseases.
